Skip to content

Total debt at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$419K+204%
CG Oncology logo
CG OncologyCGON
$7.58M+631%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$956K-16.7%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$180.9M+69.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.42M-42.5%
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $3.3M.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s total debt?
Oric Pharmaceuticals, Inc. (ORIC) reported total debt of $3.3M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s total debt changed year-over-year?
Oric Pharmaceuticals, Inc.'s total debt increased by 2.6% year-over-year, from $3.21M to $3.3M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s total debt?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s total debt has grown at a -12.1% compound annual growth rate (CAGR), from $12.44M to $7.44M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.